This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kannangai, R.
Right arrow Articles by Sridharan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kannangai, R.
Right arrow Articles by Sridharan, G.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, November 2000, p. 987-989, Vol. 7, No. 6
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Molecular Confirmation of Human Immunodeficiency Virus (HIV) Type 2 in HIV-Seropositive Subjects in South India

R. Kannangai,1 S. Ramalingam,1 K. J. Prakash,1 O. C. Abraham,2 R. George,3 R. C. Castillo,4 D. H. Schwartz,4 M. V. Jesudason,5 and G. Sridharan1,*

Departments of Clinical Virology,1 Internal Medicine Unit I,2 Dermatology,3 and Clinical Microbiology,5 Christian Medical College Hospital, Vellore, India, 632004, and Department of Molecular Microbiology and Immunology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 212054

Received 4 February 2000/Returned for modification 24 April 2000/Accepted 6 September 2000


    ABSTRACT
Top
Abstract
Text
References

Nested PCRs for human immunodeficiency virus type 1 (HIV-1) and HIV-2 were compared with immunoblot test results. Twelve of 13 immunoblot-positive HIV-2 samples were positive by PCR. There were five INNO-LIA (Innogenetics, Zwijnaarde, Belgium) and/or HIVBLOT 2.2 (Genelabs, Singapore) samples that tested positive for dual infection. HIV-1 PCR was positive in all samples, while HIV-2 PCR was positive in two and RIBA (Chiron Corporation, San Diego, Calif.) was positive for HIV-2 in three samples. Thus the prevalence of HIV-2 is accurately estimated by the use of immunoblotting, but that of HIV-1 and -2 dual infection may be overestimated.


    TEXT
Top
Abstract
Text
References

Human immunodeficiency virus type 2 (HIV-2) was first detected in West Africa, where it is seen as a major problem (2, 9, 10, 18). In Asia, 95% of the reported HIV-2 cases come from India (17, 19). The prevalence of HIV-2 in India varies regionwise, ranging between 2 and 33% of all HIV infections; these reports identify HIV-2 infection serologically (1, 11, 13, 20). Some reports indicate that immunoblotting may overestimate the prevalence of HIV-2 and HIV-1 and -2 dual infections (14, 16); thus, it is important to use molecular techniques for confirmation. We used a PCR to ascertain true HIV-2 infection in seropositive individuals and evaluated the Chiron RIBA HIV-1/HIV-2 strip immunoblot assay.

All study participants were diagnosed HIV positive at the Christian Medical College Hospital in Vellore, a tertiary-care center in southern India. Initial diagnoses were performed during the period of 1993 to 1999, as patients checked into the hospital with some other ailments or with a suspicion of HIV infection. Contact information was available on only 67 HIV-2-positive individuals, of whom only 16 (24%) responded. In addition, two individuals were contacted while in the hospital. The final study group included 15 males and 3 females belonging to the four southern Indian states. At the time of sample collection, 14 of the 18 (77.8%) individuals were asymptomatic and only two (pure HIV-2) were on antiretroviral therapy. Thirty HIV-1 immunoblot- and PCR-positive samples were also tested to assess the specificity of the HIV-2 nested PCR (nPCR). DNA was extracted from peripheral blood mononuclear cells (PBMC) using the High Pure viral nucleic acid kit (Boehringer-Mannheim, Ottweiler, Germany).

Nested PCR was done to amplify the V3-to-V5 and V3 regions of the env gene sequence for HIV-1 and HIV-2, respectively (3, 4), from all 18 HIV-infected individuals. The Expand High-Fidelity PCR system (Boehringer-Mannheim) was used for the first amplification of the HIV-2 PCR. Five microliters of the extracted DNA was subjected to first-round amplification; wherever the PCR was negative, it was repeated by increasing the input DNA to 20 µl. The expected size of HIV-1 PCR product was 700 bp, while that of HIV-2 was 542 bp. All products were detected by gel electrophoresis.

All 18 study subjects were tested using the line immunoassay (LIA) or HIVBLOT 2.2 kits; 13 were positive for HIV-2 by the kit criteria and 5 showed bands specific for HIV-1 and HIV-2. Hence these five individuals were diagnosed as having dual infections. All 13 HIV-2-positive samples showed concordant results in RIBA and LIA and/or HIVBLOT 2.2. In contrast, of the five dual-reactive samples by LIA and/or HIVBLOT 2.2, only three were positive for both HIV-1 and HIV-2 by RIBA. The remaining two samples were positive only for HIV-1. Information, including clinical status and CD4 counts of the dual infection, is shown in Table 1.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   The clinical status and CD4 counts of 5 HIV-1 and -2 dual-infected individuals and comparison of LIA and/or HIVBLOT 2.2 patterns with RIBA reactivity and PCR findings

The LIA and/or HIVBLOT (n = 13) HIV-2-positive samples tested negative by HIV-1-specific PCR, while 12 (92.3%) of these samples tested positive by HIV-2 PCR. Two of these samples were amplified only after increasing the DNA input to 20 µl, while one sample remained PCR negative. In the one HIV-2 sample which was not amplified, the presence of human DNA was confirmed by amplification of HLA genome DQ alpha-specific sequences using the GH26 and GH27 primers (5). All 30 HIV-1 PCR-positive samples were negative for HIV-2.

The five HIV-1 and -2-positive (by LIA and/or HIVBLOT 2.2) individuals also tested positive by HIV-1 PCR. Only three of these were positive for HIV-2 by RIBA, and two of these three were also positive by HIV-2 PCR (Table 2). Figure 1 shows the agarose gel with the PCR product analysis of dually reactive samples.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 2.   Immunoblot reactivity results compared to HIV-1- and -2-specific PCR findings



View larger version (78K):
[in this window]
[in a new window]
 
FIG. 1.   Gel Doc (Bio-Rad, Hercules, Calif.) picture showing specific bands for HIV-1 (700 bp) and HIV-2 (542 bp) on a 2.5% agarose gel with DNA Molecular Weight Marker IX (72-1353). Lanes 1, 3, 5, 9, and 11 show bands specific for HIV-1, amplified from the dual-reactive samples. Lanes 2 and 4 show HIV-2 PCR product of the dually positive samples, while lanes 6, 10, and 12 show the three HIV-2 PCR-negative samples. Lanes 14 and 15 show product from pure HIV-1 and HIV-2 samples, respectively. Lane 8 is the molecular weight marker. Lanes 7 and 13 are distilled-water PCR controls.

HIV-2 nPCR may have certain limitations, mainly due to low replicative capacity of the virus and low proviral copy numbers in the PBMC of infected individuals. The sensitivity of PCR for detecting proviral DNA in serologically detected HIV-2 varied from 52 to 84% in earlier studies in which Taq DNA polymerase was used for amplification (6-8, 18, 21). An improved PCR method, using XL PCR (Perkin-Elmer Applied Biosystems, Alameda, Calif.) in the first round followed by a nested PCR to amplify a sequence within HIV-2 env, increased sensitivity to 95% (3). Our study also used the same primer sets that were previously employed (3). Since the first-round primers are from the most-conserved region in pol, the chance of amplification increases through long terminal repeat including env, even though the strains show variation in the env sequence. In contrast to the V3 region of HIV-1, the V3 region of HIV-2 is more conserved. This PCR technique successfully amplified HIV-2 DNA from two patients who were on triple-drug antiretroviral therapy for 4 to 6 months and who could reasonably be expected to have extremely low viral burdens. Considering these factors, this technique can be considered a highly sensitive method for the detection of HIV-2 DNA from PBMC. Since the closely related virus HIV-1 is not amplified, this HIV-2 nPCR is highly specific.

The primary motivation for using a PCR-based diagnosis of HIV-2 infection is that in serologically detected HIV-1- and -2-positive samples, dual reactivity may be due to one of the following reasons in addition to true dual infection: extensive cross-reactivity of antibodies of either HIV type, infection by one virus and exposure to a second one, and infection with a putative intermediate virus (10). The earlier reports on PCR confirmation of dual-positive samples showed a PCR-positive rate varying from 18 to 62% (6, 14-16). Immunoblot data from this institution (the Christian Medical College Hospital), collected between 1993 and 1997, showed a prevalence of 2.1% for dual infections among the HIV infections, which was higher than that of HIV-2 infection alone (1.8%) (11). Reports from western parts of India showed prevalence rates in high-risk groups varying from 5 to 20% for dual infection, by serological methods. Such high proportions of dual infection might be inconsistent with HIV-2 infection serving a protective role against HIV-1 infection (22). However, because of cross-reactivity in immunoblotting, these figures may be falsely high. Although PCR is considered the "gold standard" for the detection of HIV-2, RIBA appears to be more specific in detecting HIV-2 than the other two immunoblot assays. Despite the limitations of the sample size, in conclusion we think that immunoblots may overestimate the prevalence of HIV-2 and that the data require reassessment with PCR testing.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Clinical Virology, Christian Medical College Hospital, Vellore 632004, India. Phone: 91 (416) 222102. Fax: 91 (416) 232035. E-mail: gsridhar{at}viro.cmc.ernet.in or g_sridharan_in{at}yahoo.com.


    REFERENCES
Top
Abstract
Text
References

1. Babu, P. G., N. K. Saraswathi, F. Deva Priya, and T. J. John. 1993. The detection of HIV-2 infection in southern India. Indian J. Med. Res. 97:49-52[Medline].
2. Brain, F., S. M'boup, F. Denis, P. Kanki, J. S. Allan, and T. H. Lee. 1985. Serological evidence of virus related to simian T-lymphotrophic retrovirus III in residents of West Africa. Lancet ii:1387.
3. Damond, F., I. Loussert-Ajaka, C. Apetrei, D. Descamps, S. Souquière, A. Leprêtre, S. Matheron, F. Brun-Vezinet, and F. Simon. 1998. Highly sensitive method for amplification of human immunodeficiency virus type 2 DNA. J. Clin. Microbiol. 36:809-811[Abstract/Free Full Text].
4. Delwart, E. L., B. Hering, A. G. Rodrigo, and J. I. Mullins. 1995. Genetic subtyping of human immunodeficiency virus using heteroduplex mobility assay. PCR Methods Appl. 4:S202-S216[Medline].
5. Erlich, H. A., and T. L. Bugawan. 1990. HLA DNA typing, p. 261-271. In M. A. Innis, D. H. Elfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and application. Academic Press, San Diego, Calif.
6. George, J. R., C. Yih-Ou, B. Parekh, K. Brattegaard, V. Brown, E. Boateng, and K. M. De Cock. 1992. Prevalence of HIV-1 and HIV-2 mixed infection in Cote d'Ivoire. Lancet 340:337-338[CrossRef][Medline].
7. Grankvist, O., U. Bredberg-Raden, A. Gustafsson, J. Albert, P. A. Albino, A. Andreasson, A. Naucler, G. Biberfeld, and G. Wadell. 1992. Improved detection of HIV-2 DNA in clinical samples using a nested primer-based polymerase chain reaction. J. Acquir. Immune Defic. Syndr. 5:286-293.
8. Grez, M., U. Dietrich, P. Ralfe, H. von Briessen, J. K. Maniar, G. Mahambre, E. L. Delwart, J. I. Mullins, and H. Rübsamen-Waigmann. 1994. Genetic analysis of human immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. J. Virol. 68:2161-2168[Abstract/Free Full Text].
9. Harrison, L. H., A. P. Da Silva, H. D. Gayle, P. Albino, R. George, S. Lee-Thomas, M. A. Rayfield, F. D. Castillo, and W. L. Heyward. 1991. Risk factors for HIV-2 infection in Guinea-Bissau. J. Acquir. Immune Defic. Syndr. 4:1155-1160.
10. Kanki, P. 1995. Epidemiology and natural history of human immunodeficiency virus type 2, p. 127-135. In V. T. Devita, S. Hellman, and S. A. Rosenberg (ed.), AIDS biology, diagnosis, treatment and prevention. Lippincott-Raven Publishers, Philadelphia, Pa.
11. Kannangai, R., S. Ramalingam, R. C. Castillo, P. G. Babu, T. J. John, G. Sridharan, and D. H. Schwartz. 1999. HIV-2 status in southern India. Trans. R. Soc. Trop. Med. Hyg. 93:30-31[CrossRef][Medline].
12. Kannangai, R., K. J. Prakash, S. Ramalingam, O. C. Abraham, K. P. Mathews, M. V. Jesudason, and G. Sridharan. 2000. Peripheral CD4+/CD8+ T-lymphocyte counts estimated by an immunocapture method in the normal healthy south Indian adults and HIV seropositive individuals. J. Clin. Virol. 17:101-108[CrossRef][Medline].
13. Kulkarni, S., M. Thakar, J. Rodrigues, and K. Banerjee. 1992. HIV-2 antibodies in serum samples from Maharashtra state. Indian J. Med. Res. 95:213-215[Medline].
14. Leonard, G., A. Chaput, V. Courgnud, A. Sangare, F. Denis, and C. Brechot. 1993. Characterization of dual HIV-1 and HIV-2 serological profiles by polymerase chain reaction. AIDS 7:1185-1189[Medline].
15. Peeters, M., G. M. Gershy-Damet, K. Fransen, K. Koffi, M. Coulibaly, E. Delaporte, P. Piot, and G. van der Groen. 1992. Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d'Ivoire. Lancet 340:339-340[CrossRef][Medline].
16. Pieniazek, D., J. M. Peralta, J. A. Ferreira, J. W. Krebs, S. M. Owen, F. S. Sion, C. F. R. Filho, A. B. Sereno, C. A. Morais de Sa, B. G. Weniger, W. L. Heyward, O. Chin-Yih, N. J. Pieniazek, G. Schochetman, and M. A. Rayfield. 1991. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS 5:1293-1299[Medline].
17. Pfutzner, A., U. Dietrich, U. Von Eichel, H. Briesen, H. D. Brede, J. K. Maniar, and H. Rubsamen-Waigmann. 1992. HIV-1 and HIV-2 infection in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of divergent HIV-1 subtype. J. Acquir. Immune Defic. Syndr. 5:972-977.
18. Richard, D., A. Wilkins, P. T. N'gum, R. Hayes, G. Morgan, A. P. Da Silva, and H. Whittle. 1994. The effects of HIV-2 infection in a rural area of Guinea-Bissau. AIDS 8:977-982[Medline].
19. Rubsamen-Waigmann, H., H. V. Brisen, J. K. Maniar, P. K. Pao, C. Scholz, and A. Pfutzner. 1991. Spread of HIV-2 in India. Lancet 337:550[Medline].
20. Rubsamen-Waigmann, H., J. Maniar, S. Grete, H. D. Brede, U. Dietrich, G. Mahambre, and A. Pfutzner. 1994. High proportion of HIV-2 and HIV-1/2 double-reactive sera in two Indian states, Maharashtra and Goa: first appearance of an HIV-2 epidemic along with an HIV-1 epidemic outside of Africa. Zentbl. Bakteriol. 280:398-402.
21. Simon, F., S. Matheron, C. Tamalet, I. Loussert-Ajaka, S. Bratczak, and J. M. Pepin. 1993. Cellular and plasma viral load in patients infected with HIV-2. AIDS 7:1411-1417[Medline].
22. Travers, K., S. Mboup, R. Marlink, A. Gueve-Ndiaye, T. Siby, I. Thior, I. Traore, A. Dieng-Sarr, J. Sankale, C. Mullins, I. Ndoye, H. Chung-Cheng, M. Essex, and P. Kanki. 1995. Natural protection against HIV-1 infection provided by HIV-2. Science 268:1612-1615[Abstract/Free Full Text].


Clinical and Diagnostic Laboratory Immunology, November 2000, p. 987-989, Vol. 7, No. 6
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Vijayakumar, T.-S., David, S., Selvaraj, K., Viswanathan, T., Kannangai, R., Sridharan, G. (2005). Performance of a Rapid Immunochromatographic Screening Test for Detection of Antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2: Experience at a Tertiary Care Hospital in South India. J. Clin. Microbiol. 43: 4194-4196 [Abstract] [Full Text]  
  • Leano, P. S., Kageyama, S., Espantaleon, A., Maniar, J., Iwasaki, M., Saple, D., Yoshihara, N., Kurimura, T., Agdamag, D. M. (2003). Introduction of Human Immunodeficiency Virus Type 2 Infection in the Philippines. J. Clin. Microbiol. 41: 516-518 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kannangai, R.
Right arrow Articles by Sridharan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kannangai, R.
Right arrow Articles by Sridharan, G.